WHO Advisory Group Recommends Two Candidate Vaccines for Ebola Trial in DRC

November 5, 2026 • PressClubAi • 2 weeks ago • 2 min read

Places named in this headline: Democratic Republic of the Congo

Expert groups convened by the World Health Organization (WHO) have recommended adding two new candidate vaccines to the ongoing Tumaini clinical trial in the Democratic Republic of the Congo (DRC) to evaluate their protection against the Bundibugyo virus. This marks the first time vaccines specifically designed for the Bundibugyo virus, the strain responsible for the country's current outbreak, will be evaluated during an active disease outbreak.

The two recommended candidates are ChAdOx1, developed by the University of Oxford and the Serum Institute of India, and Moderna’s mRNA-1469. The WHO’s independent Technical Advisory Group on Candidate Vaccine Prioritization based its recommendation on available preclinical and early clinical data, notifying the developers on Monday. The candidate vaccines will be integrated into the trial subject to national regulatory approvals.

The Tumaini trial is led by the DRC's Institut National de Recherche Biomédicale, with support from the University of Antwerp, the Institute of Tropical Medicine of Antwerp, Epicentre, Médecins Sans Frontières, the Africa Centres for Disease Control and Prevention, and the WHO. The trial utilizes a ring-vaccination strategy, administering candidates to contacts of individuals with confirmed Bundibugyo virus disease. Four vaccination rings have been established, with additional rings in preparation. The Ervebo vaccine is also being evaluated in the trial to assess its efficacy against the Bundibugyo strain.

In addition to vaccine research, clinical trials for therapeutics are progressing. The WHO-sponsored PARTNERS trial, initiated in July, is evaluating the monoclonal antibody MBP134, the antiviral remdesivir, and a combination of both in patients with confirmed disease. The treatment maftivimab is scheduled to be added to the trial, alongside a complementary post-exposure prophylaxis study testing obeldevisir.

According to the WHO, initial findings from the treatment evaluations are anticipated in the coming months, while results from the Tumaini vaccine trial are expected in early 2027.

Source

Based on material from Read source material

World Health Organization (WHO)

United Nations source who.int

Official global public health agency material; technical guidance reflects WHO assessments.

How PressClub produces articles

PressClub uses AI to write news from collected source material, with formatted source text as a fallback. The linked material provides the source’s account; this article does not establish independent verification. Read the source for its own wording and updates.

Keep Going

Read next

Catch up with a briefing, browse more stories, or share this article.

Briefing Read the latest briefing Catch the bigger picture in one recap. Coverage Explore coverage Find topics receiving more reports than usual.
Continue reading

More news to read

Browse more published news. The topic labels show what each article covers.

Browse this topic